Thank you for being part of our VeloSano family.

Our primary goal is to fund cancer research, and continue to make scientific discoveries that lead to better outcomes, and, ultimately, cures.

2017 Projects Funded

VeloSano supports projects that will build upon and transition recent advancements in cancer research into new diagnostics and therapeutics with a high likelihood of leading to successful, future, extramural grant funding. In its first three years, VeloSano has generated over $8 million dollars which has been used to finance 68 cancer research projects to bridge the funding gap for researchers and physicians at Cleveland Clinic. See below for the projects funded in 2017.


View a snapshot of the project types supported to date.

View Report


Pilot Awards

The VeloSano Pilot Awards provide seed funding for cancer research activities being performed across the Cleveland Clinic enterprise. Utilizing a competitive application and peer-review selection process, the goal of the VeloSano Pilot Awards is to support projects with a high likelihood of leading to successful, future extramural grant funding. The focus of these one year grants is to build upon and transition recent advancements in cancer genetics and epigenetics and basic and translational tumor immunology.

Impact Awards

The VeloSano Impact Awards are distributed by the VeloSano Medical Chairman to satisfy the critical needs of the Cleveland Clinic cancer program. Whether a piece of equipment, advanced technology, recruitment or laboratory expenses, the VeloSano Impact Awards are to address strategic priorities that will advance the investigational abilities in the area of cancer research. These awards are meant to ensure that our caregivers and patients have access to the best talent and technology available.

award 1
Lymphiod Malignancies

Pilot Award
Lymphiod Malignancies

Epigenetic control of the 14q32 miRNA mega-cluster is a determinant of therapeutic refractory lymphoid malignancies.

Principal Investigator

Department of Cancer Biology
Lerner Research Institute
Co-Principal Investigator

Department of Hematology and Oncology
Taussig Cancer Institute
Co-Investigator

Genomic Medicine Institute
Lerner Research Institute
Lymphoid malignancies, including chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world, are resistant to apoptosis due to overexpression of BCL-2 family members, including BCL-xL.  How expression of BCL-2 family members is regulated is important, as it may modulate sensitivity to the BCL-2 inhibitor venetoclax.  The role of microRNAs (miRNAs) in modulating BCL-xL expression and the impact of epigenetic silencing of miRNAs in lymphoid malignancies are unexplored.  We reported that increased BCL-xL expression is inversely correlated with that of miRNA-377 in cells resistant to venetoclax,  and in a panel of B-cell lymphoid lines and primary CLL cells.  Treatment of cells with the de-methylating agent 5-azacytidine (Aza) led to cell death and decreased BCL-xL expression that was prevented by mIR377 inhibition. miRNA-377 is located in the largest tumor suppressor miRNA genomic cluster in humans.  Examination of five additional miRNAs in this genomic region revealed their down-regulation in venetoclax-resistant cell lines and most chemotherapy-treated CLL patients. These findings suggest a global silencing of the DLK1-DIO3 miRNA cluster in therapy-resistant lymphoid cells, revealing a novel mechanism for promoting their chemotherapy resistance.  Our Specific Aims are:  1) To determine the methylation profile of therapy-refractory CLL, and 2) To define how methylation of the DLK1-DIO3 region miRNAs impacts therapy for lymphoid malignancies. As Aza treatment indicates that BCL-xL/miRNA-377 expression is epigenetically regulated, we will use genomic sequencing and methylation-specific PCR to define the methylation status at potential promoter and distant regulatory binding sites that regulate global-genome architecture in venetoclax and ibrutinib-resistant cells.

In Other Words

Acquired Epigenetic Changes as Therapeutic Targets in Lymphiod Malignancies

Award 2
Oral Cavity Squamous Cell Carcinomas

Pilot Award
Oral Cavity Squamous Cell Carcinomas

Mycobiome-Microbiome profiling in oral wash and normal-tumor pairs of oral cavity squamous cell carcinomas

Principal Investigator

Genomic Medicine Institute
Lerner Research Institute
Co-Principal Investigator

Cleveland Clinic
Head and Neck Oncology, Head and Neck Institute
Co-Principal Investigator

Center for Medical Mycology Department of Dermatology
Case Western Reserve University School of Medicine

Scientific evidence points to the contribution of bacteria that live in and around the body, referred to as the “microbiome,” as major contributors to human health and disease. Because bacteria living on/within the human body outnumber human cells 10:1, it makes sense that the microbiome is a large contributor to human health. Research about the bacterial communities that coexist within our bodies is still very preliminary. Only recently has the mycobiome, or the fungal communities living in and on our bodies, been realized, with some nascent thought that it too may play roles in health and disease not just in and of themselves but together with the microbiome.

Award-winning actor and producer Michael Douglas was misdiagnosed three times before he was diagnosed with advanced head and neck cancer (HNSCC). This exemplifies the paradox of tremendous advances in HNSCC research translated to patient care and the lack of improvement in clinical outcome for these patients for the last 60 years, in part due to lack of progress of diagnostic tools.

Our proposal represents a chance for a groundbreaking discovery about contributors to human health that have never before been considered. Research in HNSCC and its relation to the microbiome and mycobiome has never been performed before, and if successful, has great potential to revolutionize the way we think about cancer treatment and prevention, and could tell us not only about our risks of developing cancer, but also give rise to the earliest diagnosis and novel treatment approaches and preventative strategies for HNSCC

In Other Words

Relationship Between Head and Neck Cancer and the Microbiome (Bacterial and Fungal Community): Towards Revolutionizing Treatment and Prevention

Award 3
Glioblastoma

Pilot Award
Glioblastoma

Increased macropinocytosis by tumor-associated endothelial cells requires integrin α3β1/CD151 and promotes angiogenesis

Principal Investigator

Department of Cancer Biology
Lerner Research Institute
Co-Investigator

Professor, Department of Molecular Biology and Microbiology
Case Western Reserve University
Collaborator

Department of Cancer Immunology and Virology
Dana-Farber Cancer Institute

Glioblastoma (GBM) tumors are fed by newly formed blood vessels (angiogenesis) that also promote resistance to chemo- and radiation-therapy; however, anti-angiogenic therapies are only of limited success. This suggests a critical gap in the understanding of angiogenesis in tumors. We propose a highly novel hypothetical model of angiogenesis in GBM in which the cells (endothelial cells) that line those blood vessels that are closely associated with the tumor (TECs) develop robust macropinocytic capabilities, Macropinocytosis is a mechanism used by cells to take up extracellular fluids and proteins. The molecules that are taken up can be routed to lysosomes that recycle parts of large molecules to support cell growth. Potentially, macropinocytosis can support cell growth in the tumor environment where rapidly growing cells cause nutrient deprivation. Specifically, we propose that (i) enhanced macropinocytotic capability of the TECs is dependent on a collaborative partnership between two cell surface molecules, CD151 and integrin α3β1; and (ii) that the recycling of the macropinocytosed material by the lysosomes promotes angiogenesis. We will test the hypothesis in vitro and in vivo using state-of-the-art models including 3-dimensional matrices and intracerebral mouse models of GBM that utilize mouse cells. The significance of our hypothetical model is that it indicates how the numerous environmental, cellular and molecular events that affect tumor-associated angiogenesis act together and thus suggests new candidate therapeutic targets with potential to ensure sustained inhibition of this type of angiogenesis. The clinically-relevant study design forms the framework necessary for planned, future testing of these targets.

In Other Words

Identifying Better Targets for Anti-Angiogenic Therapies to Treat Glioblastoma Patients

Award 4
Breast Cancer

Pilot Award
Breast Cancer

The Microbiome and Neoadjuvant Theray in HER-2 Positive Breast Cancer

Principal Investigator

Breast Services
Digestive Diseases and Surgery Institute
Co-Investigator

Pathology and Laboratory Medicine Institute
Co-Investigator

Pathology and Laboratory Medicine Institute
Co-Investigator

Taussig Cancer Institute
Co-Investigator

Digestive Diseases and Surgery Institute

The microbiome refers to all of the organisms within and on the human body. There is growing recognition that an individual’s microbiome has very important effects on the physiology of health and disease. This project will focus on an aggressive form of breast cancer (BC), HER-2 positive BC. Currently, many patients with HER-2 positive BC are treated initially with HER-2 targeted medical therapies. However, around half of patients treated with these therapies do not have a complete response to the medical therapy. Factors related to an incomplete response are currently unknown. HER-2 targeted therapies are thought to work via activation of the immune system. There is also a growing recognition that the gastrointestinal microbiome has major impacts on the immune system and how the body responds to chemotherapy. Identification of microorganisms specifically associated with HER-2 positive BC and how these are associated with extent of response to therapy and its relationship to the immune system would be a major advance and could open the door to new interventions aimed at improving the efficacy of targeted therapies in HER-2 positive patients.

In Other Words

Determining Response of Microorganisms to Chemotherapy before Surgery in Breast Cancer

Award 5
Large B Cell Lymphoma

Pilot Award
Large B Cell Lymphoma

Molecular basis of relapse in diffuse large B cell lymphoma.

Principal Investigator

Department of Immunology
Lerner Research Institute
Co-Investigator

Department of Hematology and Medical Oncology
Taussig Cancer Institute
Principal Investigator

Department of Clinical Pathology
Pathology and Laboratory Medicine Institute

B lymphocytes are white blood cells of the immune system that protect us from infections. The growth of these cells is tightly regulated; however, their aberrant regulation can lead to development of cancer. Diffuse large B cell lymphoma (DLBCL) is the most common and aggressive type of lymphoid cancer. A third of DLBCL patients either do not respond to initial therapy or relapse after standard chemotherapy. Only ten percent of the relapsed patients achieve three-year progression-free survival. Therefore, relapse is a significant clinical problem and an unmet medical need, underscoring the urgency for novel treatment approaches for relapsed DLBCL. Unfortunately, the molecular mechanisms that form the basis of relapse in DLBCL are poorly understood. DLBCL tumors exhibit considerable variability at the biological, genetic and clinical levels. However, there is limited knowledge on the genetic evolution of relapsed tumors. In particular, it is not known whether particular alterations in the patients’ genetic makeup occur after treatment, which enable certain DLBCL cells to attain resistance. These changes may cause some residual resistant cancer cells to bounce back and cause relapse. In order to fill gaps in the molecular understanding of relapsed DLBCL we propose to employ a variety of modern genomic technologies, which will pinpoint the underlying factors and thus pave the way for development of novel treatment approaches and clinical management.

In Other Words

Understanding the Molecular Basis of Relapse in Diffuse Large B Cell Lymphoma

Award 6
Prostate Cancer

Pilot Award
Prostate Cancer

Targeting the interaction between the drivers of lethal cancer progression as a novel treatment strategy for prostate cancer

Principal Investigator

Department of Cancer Biology
Lerner Research Institute

Prostate cancer causes approximately 30,000 deaths in the US annually. Failure of hormone therapy is a major contributor to these deaths. Hormone therapy prevents testosterone, the most important male hormone that drives prostate cancer growth, from being made or being active. At first, hormone therapy results in remission.  Unfortunately, eventually hormone therapy fails and an advanced form of prostate cancer that kills men develops. Our laboratory has discovered a novel mechanism of communication, or signaling, that controls the growth of prostate cancer cells. This pathway involves the action of a class of proteins known as mutant p53 that causes development of the form of prostate cancer that kills men, and is active in prostate cancer cells before and after hormone therapy. Targeting this pathway may be a new option to treat patients with advanced prostate cancer. Here, we propose preclinical studies using cell and mouse models that represent the deadly form of prostate cancer that recurs after hormone therapy. We will define how components of this signaling pathway interact with each other and with mutant p53 before and after hormone therapy. We will determine how well disrupting the interactions in this signaling pathway controls growth and spread of prostate cancer, how long remission lasts, and whether the development of deadly prostate cancer can be prevented. These studies will give us the information needed to develop drugs to target this signaling pathway and tell us whether they can be used to treat men in whom hormone therapy has stopped working.

In Other Words

Targeting the Interaction Between the Drivers of Lethal Cancer Progression as a Novel Treatment Strategy for Prostate Cancer

Award 7
Colitis-Associated Cancer

Pilot Award
Colitis-Associated Cancer

Epigenetic histone modifications track the pathogenesis of colitis associated cancer in primary human organoids

Principal Investigator

Stem Cell Biology/Regenerative Medicine
LRI and Digestive Disease and Surgery Institute (DDSI)

Colitis-Associated Cancer (CAC) of the colon is a devastating consequence of the chronic inflammatory bowel disease called ulcerative colitis (UC). About one million Americans have inflammatory bowel disease, and their CAC risk factor is 3 to 5-fold higher than the rate of sporadic colorectal cancer in the general population. The exact causes of CAC remain unknown, precluding development of effective preventive and curative disease treatments. Drs. Huang and Lefebvre propose here to combine expertise and efforts to help lifting this knowledge gap. Preliminary data suggest that colon samples harvested from patients at various stages of colon disease can be amplified in vitro as organoids that maintain normal or disease features. Aim 1 of this project is therefore to create the first-ever bank of patient-derived colitic, dysplastic, and CAC organoids to provide currently lacking experimental models. Aim 2 is to start using this bank to decipher disease mechanisms. Since several cancer types are known to be due to gene mutations that eventually result in broad changes in histones (proteins associated with and regulating the genome) and thereby in global changes in gene expression, Aim 2 will test the hypothesis that CAC may be due to yet-unknown mutations that cause permanent histone and gene expression changes. This will be done using cutting-edge high-throughput approaches to sequence the genome, histone modifications and expressed genes. Altogether, this pioneering project is expected to generate novel, experimental models and promising data to support large-scale follow-up projects to reveal mechanisms causing CAC and identify effective disease treatments.

In Other Words

Using Genomics and Epigenomics on Primary Tissue Organiods to Discover Causes of Colitis-Associated Cancer

Award 8
Rectal Cancer

Pilot Award
Rectal Cancer

Coenzyme A synthase: A Novel Target for Rectal Cancer Radiation Sensitivity

Principal Investigator

Department of Colorectal Surgery
Department of Stem Cell and Regenerative Medicine
Digestive Disease and Surgery Institute
Lerner Research Institute
Taussig Cancer Institute

Rectal cancer is a deadly disease that often requires treatment from multiple medical and surgical specialties. For locally advanced rectal tumors, it is recommended that patients receive radiation along with chemotherapy to help kill the tumor before surgery. Patients who have a good response to chemoradiation have a better cancer outcome than those that do not have a good response. There is large variability in tumor response and there is a need for novel approaches to increase the extent and improve response rates. Using advanced technology to analyze patients’ rectal cancers, our research team has identified several genes that are important for response to chemoradiation therapy and are related to cancer outcomes. We have discovered that increased levels one of these genes, coenzyme A synthase (CoASy), is strongly associated with a poor response to chemoradiation and that blocking it may improve the response. This research project will manipulate the expression of this gene and then analyze the effect that changing CoASy levels has on the ability of radiation to kill rectal cancer. In doing this, we will also study the biologic mechanisms through which this process works so that we can find new ways to intervene. Lastly, this project will search for and develop novel compounds that could potentially serve as new drugs to inhibit this protein and thus improve radiation response. The ultimate goal of this work is to take what is learned and move it towards the clinical application of developing new ways to help cure rectal cancer.

In Other Words

Developing New Ways to Help Cure Rectal Cancer

Award 9
Glioblastoma

Pilot Award
Glioblastoma

Development of a cancer stem cell targeting strategy via disrupting cell-cell communication

Principal Investigator

Department of Cellular and Molecular Medicine
Lerner Research Institute
Co-Investigator

Translational Hematology and Oncology Research
Taussig Cancer Institute
Principal Investigator

Translational Hematology and Oncology Research
Taussig Cancer Institute

Direct cell-cell communication is vital for organ development as it allows cells to modify their behavior in a synchronized manner. This process is dysregulated in tumors, and the proteins that facilitate cell-cell communication, termed connexins, are frequently reduced in tumors. This observation led to the hypothesis that connexins suppress tumor growth. However, we have revisited this hypothesis based on observations that increased cellular density is a hallmark of malignant tumors, thereby increasing the opportunity for direct cell-cell communication. In models of glioblastoma, the most malignant primary brain tumor, we observed that tumor cells use connexins to directly communicate in a rapid and coordinated manner. We identified an individual connexin (connexin 46, Cx46) that is elevated in cancer stem cells, a therapeutically resistant subpopulation of tumor cells. Reducing Cx46 levels in these cells attenuated tumor growth, suggesting that targeting Cx46 may be a promising therapeutic strategy. However, compounds that specifically target Cx46 have yet to be identified. To detect Cx46-specific compounds, we developed a cell-based model of Cx46-dependent cell-cell communication. Using this platform, we screened FDA-approved compounds and identified clofazimine, an anti-leprosy drug, as one of the top candidates that reduced cell-cell communication. This proposal will test the efficacy of clofazimine against cancer stem cells and its ability to reduce glioblastoma growth. In addition, medicinal chemistry will be used to generate clofazimine analogs with increased efficacy. Treating glioblastoma remains a challenge, and we propose to develop a new treatment strategy by repurposing an FDA-approved drug to reduce cell-cell communication.

In Other Words

Developing a New Treatment Strategy for Glioblastoma by Repurposing an FDA-Approved Drug to Reduce Cell-Cell Communication

Award 10
Colorectal Cancer

Pilot Award
Colorectal Cancer

Genome Organizer-Mediated Repression of LINE-1 Retrotransposition during Inflammation

Principal Investigator

Cellular and Molecular Medicine
Lerner Research Institute
Genomic instability is a major driver of tumorigenesis.  LINE-1 (L1) retrotransposons are DNA elements within the human genome that can mobilize through a process called retrotransposition, and their mobilization can cause genomic instability.  Therefore, cells employ a number of different mechanisms to inhibit L1 retrotransposition.  Proteins which organize the global DNA structure are instrumental in generating and maintaining DNA contacts that regulate transcription and many other essential cellular functions.  However, the ability of genome organizers to modulate L1 activity have not been thoroughly tested.  Studying the interplay between genome organizing proteins and L1 retrotransposons in cancer and non-cancerous cells will identify new proteins and pathways whose activities could be harnessed as therapeutics to prevent genome instability and tumor development associated with L1 retrotransposition.  Our preliminary data is the first to show that a major genome organizing complex, Condensin II, actively represses L1 retrotransposition.  Furthermore, we show that low levels of Condensin II subunit, CAP-D3, inversely correlate with high levels of L1 retrotransposition in patient-derived tumor cells from a type of cancer that develops in inflamed tissues.  In this proposal, we will utilize retrotransposition assays, immunoprecipitation coupled with Mass spectrometry analyses, and molecular biological techniques to determine whether genome organizers cooperate with inflammatory signaling pathways to repress L1 in patient-derived cells.  Collectively, the results of these studies will further our understanding of L1 biology, increase our knowledge of the tumor suppressing activities of genome organizing proteins, and identify novel cell defense mechanisms important for repression of L1 mobilization during inflammation.

In Other Words

Investigating Genomic Instablility in Inflammation-Driven Colorectal Cancer

Award 11
Tumor Suppression

Pilot Award
Tumor Suppression

High molecular weight kininogen: A novel tumor suppressor

Principal Investigator

Department of Hematology and Solid Tumor Oncology
Taussig Cancer Institute
High molecular weight kininogen (HK) is a plasma protein that plays important roles in the contact activation and kallikrein-kinin systems. HK is not necessary for normal hemostasis (clotting), but may play a role in pathologic thrombosis. HK can be clipped by plasma kallikrein to release a short fragment (bradykinin) from the middle of HK, leaving behind a two-chain molecule (HKa) held together at both ends by a disulfide bond. HKa adopts a dramatically different shape after this cleavage event, accompanied by new biologic properties. These include the ability to kill proliferating blood vessel lining (endothelial) cells, and block the formation of new blood vessels (angiogenesis). We prepared a mouse that lacked kininogen, finding that tumors implanted in this animal grew larger and more quickly than those in normal mice, suggesting that kininogen may function as a tumor suppressor. Tumors in kininogen-deficient mice had more blood vessels, and produced higher levels of certain proteins that promote tumor growth and invasion. These findings suggest that kininogen may function as a tumor suppressor by inhibiting several different processes within tumors, including the growth of new blood vessels and the behavior of both cancerous and non-cancerous (stromal) cells. This application will seek to determine which cells are affected by kininogen and examine the underlying molecular mechanisms. The goal of these studies is to determine whether certain pieces of kininogen with anti-tumor activity, as well as certain pathways activated by kininogen in tumors, can be identified and developed as agents effective in cancer treatment.

In Other Words

Focusing on High Molecular Weight Kininogen (HK), a Protein Found in Blood that We Have Found to Function as a Novel Tumor Suppressor Protein

Award 12
Leukemia

Pilot Award
Leukemia

Targeting the SET-SETBP1-PP2A oncogenic nexus by small molecules to prevent cancer progenitor cell growth and induce terminal differentiation and death

Principal Investigator

Dept. of Translational Hematologic & Oncology Research
Taussig Cancer Institute
Co-Investigator

Dept. of Translational Hematologic & Oncology Research
Taussig Cancer Institute
To maintain the ability of self-renewal cells have developed a complex signaling network that involves phosphorylation (adding a phosphate group via a kinase utilizing an ATP molecule) or de-phosphorylation (removing a phosphate group via a phosphatase enzyme). Generally, phosphorylation transduces a pro-survival signal that is generally controlled by phosphatases. The imbalance in the coordinated activity of kinase and phosphatase leads to oncogenic pressure and uncontrolled growth. Over the past decade, an emerging role of phosphatases in the pathogenesis of hematologic malignancies and solid tumors has been established. One of the major tumor suppressor protein phosphatase is PP2A, which accounts for the majority of de- phosphorylation of serine and threonine residues in a protein in mammals. A number of studies have demonstrated that suppression of PP2A expression and/or activity can contribute to leukemogenesis in several hematological malignancies. Likewise, overexpression or mutations in certain proteins that inhibit PP2A activity, e.g., SET and its associated SETBP1, turn off PP2A function and tilt the signaling balance towards leukemic progression. Our recent discovery in the Department of Translational Hematology & Oncology Research of Taussig Cancer Institute demonstrates that a stabilizing mutation in SETBP1 traps SET-PP2A into inactive state which may be responsible for leukemia progression. Therefore, this proposal, will specifically target the SETBP1-SET-PP2A nexus using structure based drug design to prevent or intercept this SETBP1 caused SET-PP2A inactive state thus killing leukemic cells while sparing normal hematopoiesis.

In Other Words

Using Computer Aided Structure Based Drug Design, our Project Will Specifically Target this Mutation Intending to Kill Leukemic Cells While Sparing Normal Hematopoiesis

Award 14
Prostate Cancer

Pilot Award
Prostate Cancer

Determining the role of aberrant glucocorticoid metabolism in enzalutamide-resistant prostate cancer

Principal Investigator

Department of Cancer Biology, Department of Hematology and Oncology, Department of Urology
Lerner Research Institute, Taussig Cancer Institute, Glickman Urological and Kidney Institute
Collaborator

Department of Hematology and Oncology
Taussig Cancer Institute
Collaborator

Department of Urology
Glickman Urological and Kidney Institute
Castration-resistant prostate cancer (CRPC) is the second leading cause of cancer death for men in the United States.  Metastatic prostate cancer usually responds initially to therapy that deprives the tumor of androgens (male hormones), i.e., medical or surgical castration.  Unfortunately, tumors eventually recur as CRPC, which is frequently driven by continued hormonal stimulation of the androgen receptor (AR).  Enzalutamide is a new hormonal therapy that is the most potent AR blocker used for treatment of CRPC. Although tumors frequently respond to enzalutamide, treatment resistance invariably occurs and is mediated by an increase in another steroid hormone receptor, the glucocorticoid receptor (GR).  GR stimulates expression of half of the same genes that the AR does.  Consequently, the increase in GR renders enzalutamide ineffective. Treatments that would directly target GR to prevent enzalutamide resistance are problematic because total GR blockade would be lethal.  Therefore, identifying a drug target that occurs only in the tumor and will halt GR stimulation and enzalutamide resistance is clearly necessary. 
 
We hypothesize that a tumor-specific metabolic mechanism is required for GR stimulation and enzalutamide resistance.  Our preliminary data suggest that the increase in GR that occurs with enzalutamide treatment is accompanied by loss of the 11βHSD2 enzyme, which in turn is responsible for enzalutamide resistance.  This proposal will elucidate metabolic mechanisms that enable resistance to enzalutamide. We anticipate that the insights gained from this proposal will directly lead to the identification of new drug targets and the development of improved treatment strategies for more effective clinical therapy.

In Other Words

Identifying Improved Treatment Strategies for Castration-Resistant Prostate Cancer

Award 15
Prostate Cancer

Pilot Award
Prostate Cancer

Targeting HDL Metabolism to Prevent Progression to Lethal Prostate Cancer

Principal Investigator

Department of Cellular & Molecular Medicine
Lerner Research Institute
Collaborator

Department of Cancer Biology
Lerner Research Institute and The Glickman Urological & Kidney Institute
Prostate Cancer is the most common form of cancer and the second leading cause of cancer-related death in men in the US.  Prostate cancer is driven by androgen signaling, and androgen deprivation therapy is a standard treatment.  However, many men develop resistance to androgen deprivation, demonstrating the need for novel therapies.  Our goals are to characterize strategies to alter HDL biogenesis and uptake in order to treat prostate cancer. High density lipoprotein (HDL) is formed by the interaction of a secreted protein called apoA1 with a cell membrane protein called ABCA1.  This interaction leads to the cellular removal of cholesterol and lipids, including a special signaling lipid called “PIP2”, onto nascent HDL.  Plasma HDL can deliver these lipids to target tissues via the HDL receptor, scavenger receptor-BI (SRB1).  The cellular removal or delivery of PIP2 can regulate cell proliferation, as PIP2 is part of a signaling pathway that promotes the activation of a key cell growth and survival protein involved in many types of cancer.  We performed bioinformatic analyses and discovered that SRB1 is often up regulated in prostate cancer and in metastatic vs. non metastatic prostate cancer.  Thus, we developed strategies to alter ABCA1 and SRB1 expression in prostate cancer cells in order to demonstrate that either blocking SRB1 or inducing ABCA1 will suppresses prostate cancer through alteration of PIP2 and cholesterol metabolism.  This study can provide critical pre-clinical data to support the development of anti-SRB1 and/or pro-ABCA1 therapies to treat prostate cancer in men.

In Other Words

Exploring the Connections Between HDL, Cholesterol, and Prostate Cancer to Develop New Therapies to Halt Prostate Cancer Progression

Award 16
Multiple Myeloma

Pilot Award
Multiple Myeloma

Targeting macrophage migration inhibitory factor (MIF) to treat multiple myeloma

Principal Investigator

Department of Cancer Biology
Lerner Research Institute
Collaborator

Department of Cancer Biology
Lerner Research Institute
Multiple myeloma (MM) is an incurable cancer of the blood that is characterized by tumor cell accumulation in the bone marrow (BM). Treatments are available, but the tumor cells eventually become treatment-resistant. MIF, a molecule involved in cell-to-cell communication, is expressed by human MM cells, and high expression positively correlates with advanced disease and poor survival.  Among other discoveries, we have found that human MM cells that do not express MIF do not accumulate in the protective BM and can be killed with chemotherapy. We hypothesize that MIF contributes to MM drug resistance and inhibiting MIF activity will greatly enhance the efficacy of chemotherapy for MM. In this project, we will determine how to target this molecule to enhance myeloma cell sensitivity to chemotherapy.

In Other Words

Targeting Microphages by Using Colony-Stimulating Factor 1 Receptor Blocking mAbs to Treat Myeloma

Award 18
Adolescent and Young Adult Lymphoma

Impact Award
Adolescent and Young Adult Lymphoma

Quantification of therapeutic responses in pediatric and AYA Hodgkin Lymphoma patients via detection of circulating tumor DNA

Principal Investigator

Pediatric Hematology Oncology and Blood and Marrow Transplantation
Children's
Lymphoma is a neoplasm caused by malignant transformation of lymphoid cells; it is the third most frequent (12-15%) malignancy in children and the most frequent type of malignancy in early AYA population (15-24 years of age). Advances in understanding of lymphoma biology led to development of the risk- and response-adapted therapies, which made lymphomas to be one of the most curable pediatric cancers. The disease-free survival following completion of therapy exceeds 85% for the majority of lymphoma patients. FDG-PET/CT is an important diagnostic tool for pre-treatment clinical risk stratification as well as assessment of the therapeutic response following chemotherapy. However there is concern about increased risk for secondary cancer from radiation exposure in addition to chemotherapy effect.

The Adaptive immunoSEQ® for MRD Assay uses NGS technology for the detection, quantification and analysis of minimal residual disease/minimal detectable disease (MRD/MDD) in patients previously diagnosed with lymphoid leukemia. The assay employs multiplex PCR, high throughput sequencing, and a proprietary algorithm for the purpose of evaluating lymphoid clonal distribution and expansion in genomic DNA extracted from samples such as lymph node, peripheral blood or bone marrow. The detection of the acellular, patient-unique, cHL-only specific ctDNA is a truly pioneering approach capable of documenting complete remission and/or disease recurrence at the subcellular level. it could decrease risk of secondary cancers by eliminating radiation exposure and it also will help with children quality of life to eliminate the need for sedation that is required for many during PET CT scan.

In Other Words

Determining Complete Remission of Adolescent and Young Adult Lymphoma at a Subcellular Level Without Need to Do Imaging

Award 19
Brain Metastases

Pilot Award
Brain Metastases

Brain Metastases Research Program

Principal Investigator

Brain Tumor and Neuro-Oncology Center and Hematology and Oncology
Neurological Institute
Brain metastases is a serious complication of cancer that causes significant morbidity for patients. More than 300000 patients are diagnosed with brain metastases in United States every year. Traditionally, local therapies including surgery, whole brain radiotherapy, and stereotactic radiosurgery (SRS), played an important role in the management of brain metastases. However, this is rapidly changing with recognition of numerous new driver somatic mutations; targeted therapies are changing the landscape of treatment in brain metastases. Emerging data also supports use of immunotherapy in the treatment of these patients. Our research program focuses on identifying the genomic signatures in brain metastases and its impact on outcomes of this patient population. We have generated a large body of data to define prognostic indices in brain metastases. Our program is leading  several clinical trials focusing on use of targeted therapies and immune checkpoint inhibitors in brain metastases. Velasano impact award will help our Center to identify the genetic changes that give rise to resistance in brain metastases and to use this information to develop personalized treatment strategies. These funds will help facilitate novel clinical trials of SRS, targeted and immunotherapy to define new paradigms in the management of these patients. 

In Other Words

Developing Personalized Clinical Trials for Brain Metastases Focused on Genetic Alterations

Case Comprehensive Cancer Center
Multiple Cancer Types

Pilot Award
Multiple Cancer Types

Cleveland Clinic is part of the Case Comprehensive Cancer Center (CCCC), which is designed to promote research collaboration across the three member institutions: Cleveland Clinic, Case Western Reserve University and University Hospitals. Team science is increasingly important for successful cancer research, and the CCCC is an excellent example of such teamwork across these three organizations.
CCCC had numerous teams participate in VeloSano 3, and as part of our collaboration they received $350,000 of the funds raised in 2016.
Below is a summary of the funded CCCC Pilot Awards:

Inhibitors to the human UNG by high-throughput small-molecule screening (HTS)
PI: Stanton Gerson, MD

Novel Approaches for Targeting PPP2R2A-Defective Cancer Cells by ATR and CHKI Inhibitor
PI: Junran Zhang, M.D., Ph.D.
This application aims to develop new approaches for treating lung/ovarian cancers with defective PPP2R2A. The central hypothesis is that CHK1 and ATR inhibitors specifically target PPP2R2A-defective ovarian/lung cancers by enhancing replication stress (RS) due to a synthetic lethality. Two specific aims include: (1) Determine the mechanisms of PPP2R2A on CHK1 or ATR inhibition-induced RS; (2) Assess the anti-tumor activities of CHK1 and ATR inhibitors.

Hematologic Biomarkers of Treatment Response and Recurrence in Patients with Glioblastoma
PI: Jill Barnholtz-Sloan, Ph.D.
The application proposes to test and identify a blood marker that will differentiate recurrent GBM from radiation necrosis based on preliminary data that is now in press in Journal of Neuro-Oncology. The findings from this proposal can help identify patients with recurrence or not without the need of a brain tumor biopsy.

Develop GPT2 inhibitors to Target PI3KCA-Mutated Colorectal Cancers
PI's: Zhenghe John Wang, Ph.D. and Drew Adams
The goal of this proposal is to optimize small molecular inhibitors of glutamate pyruvate transaminase 2 (GPT2) to treat colorectal cancers (CRCs) with PIK3CA mutations given that CRCs with PIK3CA mutations are addicted to glutamine. The research team was awarded a VeloSano grant last year and was successful in developing an enzymatic assay for GPT2 and ran a high-throughput screen of 50,000 small molecules to identify 15 hits in vitro GPT2 inhibitors. Building on these results, the current proposal focuses on performing the initial round of chemical optimization of the confirmed lead series using commercially available analogs and to evaluate leading GPT2 inhibitors in cell culture models of PIK3CA-mutant colon cancer. 
 
Roles of UbcH7 in Tumorigenesis and Therapy Response
PI: Youwei Zhang, Ph.D. (PI); Co-Investigators: Ruth Keri, Nathan Berger, Ming Li
The application seeks to understand the role of an ubiquitin E2 Conjugating enzyme in promoting cancer progression and regulating the therapeutic response in breast cancer. The authors include a heavy dose of preliminary data that suggest that gross depletion of UbcH7 affects cell cycle control and lamina structure, at least in A549 cells. Based on these data, the authors will correlate the loss and/or overexpression of UbcH7 in mouse HER2+ BC models with tumor growth and metastasis and further characterize UbcH7 expression with HER2 inhibitor outcome.

Tyrosine Kinase Inhibitors and Cardiovascular Event in CML
PI: Alvin Schmaier, M.D.
The goal of this application is to study the mechanisms by which the tyrosine kinase inhibitor Ponatinib (Poni) induces cardiovascular events during CML treatment. The central hypothesis is the Poni’s inhibition of ABL1 kinase and activation of platelet GPVI results in reduced antithrombotic vascular function and activated platelets, leading to heighten arterial thrombosis risk. There are three specific aims: (1) Characterize the mechanisms by which Poni reduces the antithrombotic nature of the vascular wall; (2) Characterize the mechanisms by which Poni increases platelet activation; (3) Characterize the in vivo effects of PPARr and Sirt1 agonists to block poni-induced heightened thrombosis risk in mice. The potential outcome of the proposed study may help to prevent the prothrombotic effects of Poni in vivo and reduce side effects during CML treatment with the TK inhibitor.

A High-Throughput Screen for Inhibitors of Cancer Stem Cell Plasticity
PI: Mark W. Jackson, Ph.D. Co-Investigator: Drew Adams 
This project seeks to identify chemical inhibitors capable of inducing pancreatic cancer cell differentiation away from cancer stem cell phenotypes. Based on the successful completion of proof-of-principle analysis of a 3100+ compound library, the applicants now aim to expand their screening efforts to a 50,000 compound library.

HES1-loss Mediates Immune-suppressive Microenvironment in Serrated Pathway of Colon Carcinogenesis
PI: Lan Zhou, M.D., Ph.D.
The proposal is focused on investigating a link between HES1 and both methylation changes and immunological effects in colorectal carcinoma and a precursor lesion (sessile serrated adenoma). The investigators have obtained correlative data suggesting a link and this proposal will provide a much stronger mechanistic connections that will be necessary for national level funding. If positive results are obtained the results would be both significant and impactful.

Why I Ride

Because together we’re stronger
Bigger infinities
Cancer survivor & VeloSano grant recipient
depending on research to bring them a cure.
Diagnosed with Thyroid cancer in 2005
Family & Friends Beating Cancer
For all who are fighting cancer
For my brain tumor team at Cleveland Clinic
For those who bravely battle cancer!
For those who’ve won & those who fight
I am a cancer survivor!!
I am a grateful cancer survivor.
I ride because I’m happy to be alive!
I ride for all Cancer Warriors!
I ride for all those in treatment
I ride for every cancer patient
I ride for every sufferer and survivor
I ride for survivors everywhere…
I ride so others can be living hope!
I ride to get one step closer to a cure!
I’m a stage IV oral cancer survivor!
In Honor Of All Cancer Survivors
Myself and my fellow survivors!
Research is the answer!
Support of all cancer survivors
To find a cure for me and anyone else
To Give A Voice To Patients Who Need One
To honor cancer survivors
To honor the sick’s courage

Riding For Pediatric Patients

square image
square image
square image

Dr. Rabi Hanna is a VeloSano Rider and recipient of VeloSano 3 funds. Dr. Hanna, who is also the Chair of the Pediatric Hematology, Oncology, Blood & Marrow Transplantation at Cleveland Clinic Children’s, rides in VeloSano for a very special patient… his friend Maisie.

For Maisie, life before she was diagnosed with Severe Aplastic Anemia was beautiful. But quickly, her world was turned upside down. Plastic Anemia is a condition where the patient’s bone marrow does not produce platelets or red blood cells. It also produces very little white cells to fight infection.

After five medications proved to be unsuccessful, Dr. Hanna used an innovative medication that enabled Maisie to sustain life by bringing her platelets out of crisis mode and into normal levels.

The only cure to help her get better was replacing her bone marrow. Unfortunately, none of Maisie’s siblings were a bone marrow match so her family began a national search and spearheaded several bone marrow drives. After four months of waiting, a match came into the database for Maisie.

During the treatment and transplant process, Dr. Hanna formed a special bond with Maisie and her family. Dr. Hanna earned Maisie’s trust by allowing her to give him homework assignments as she was going through some difficult treatments. Maisie did just that, asking Dr. Hanna to complete assignments such as dying his hair pink, shaving his head or simply joining her for a dance party. Maisie loved Dr. Hanna and because of that trust, she was willing to do some really hard things because he asked her to do so.

After 7 weeks in the hospital, Maisie finally went home. The transplant was working. But unfortunately, a few weeks later, the donor marrow produced abnormal antibodies causing Maisie to return to Cleveland Clinic Children’s. Dr. Hanna was not going to give up and used an innovative medication that eventually improved her condition and increased her white blood cell counts.

Thanks to the innovative care that Dr. Hanna and his team were able to provide Maisie, her counts are now stable and she is doing well. During VeloSano 3, Maisie served as an honorary Pace Car Rider to launch the 12-mile Fun Ride. She was so proud to see Dr. Hanna riding in her honor and hopes to soon join him for the ride.

VeloSano funds many types of cancer research, including Pediatric research at Cleveland Clinic. Most recently, Dr. Hanna received funding from VeloSano 3 to support his research in Hodgkin Lymphoma. These funds allow him to continue helping and caring for other pediatric patients like Maisie.

Numbers & Lists

 
 

Top Fundraisers

2016 Top Fundraising Riders

  1. Joanne Cohen
    $172,262
  2. Marc Harrison
    $150,105
  3. Stewart Kohl
    $142,837
  4. Bob Rich
    $43,070
  5. Paul Dolan
    $40,939
  6. Kelly Tompkins
    $32,655
  7. Mark Snyder
    $30,775
  8. Mike Maroone
    $24,040
  9. Len Pagon
    $23,414
  10. Bill Mulligan
    $22,804

2016 Top Fundraising Virtual Riders

  1. Ken Guest
    $12,035
  2. Jaroslaw Maciejewski
    $9,255
  3. Jorge Garcia
    $8,210
  4. Nicole Peters
    $4,971
  5. Zumi Pig
    $3,555
  6. Brian Bolwell
    $3,050
  7. Ryan Schreiber
    $2,757
  8. Greg Mueller
    $2,525
  9. Shlomo Koyfman
    $2,435
  10. Bassam Estfan
    $2,395

2016 Teams

Team Name Riders & Virtual Riders Total Dollars Raised
Are We There Yet? 4 $4,125.00
Ave Maria 7 $7,505.00
BDO 21 $37,221.00
Bellwether Enterprise Cleveland 7 $10,571.00
BIG GALOOTS BICYCLE CLUB (Rich Foods) 76 $184,601.84
Bike Shaker/Shaker Historical Society 2 $3,263.00
Blue Energy (Hilton Cleveland Downtown Hotel) 4 $2,200.00
BRG 1 $25.00
Cardinal Health 70 $90,032.06
CardinalCommerce Corporation 4 $4,520.00
Case CCC: Case Comprehensive Cancer Center Team 55 $74,604.16
Case CCC: Cell Cycles 8 $2,155.00
Case CCC: The Nanoman 3 $2,445.00
Case HEC | Donley’s 10 $20,758.50
CBIZ 5 $8,078.00
CBRE Cleveland 28 $48,198.57
Centers For Dialysis Care 2 $1,445.00
CHAIN REACTION CYCLING TEAM (Adcom) 26 $33,179.75
Cleveland Clinic: 4TheRide 2 $1,225.00
Cleveland Clinic: Akron General 24 $20,486.12
Cleveland Clinic: Bike Like a Champion Today (Leadeship Team) 11 $11,385.00
Cleveland Clinic: BOC Independence 5 $6,917.00
Cleveland Clinic: Brain-iacs (Neurosurgery) 8 $5,676.00
Cleveland Clinic: Cleveland Clinic Children’s 16 $20,040.05
Cleveland Clinic: Fairview Hospital 23 $15,315.21
Cleveland Clinic: Florida Maroone Cancer Center 7 $33,342.00
Cleveland Clinic: H60 (Neuroscience) 2 $2,612.00
Cleveland Clinic: LRI (Lerner Research Institute) 31 $31,876.21
Cleveland Clinic: Make it Rain (Philanthropy) 47 $83,811.22
Cleveland Clinic: Medina 3 $1,701.00
Cleveland Clinic: ONEHR Rides 9 $12,667.00
Cleveland Clinic: Pepsin Pedalers (Digestive Disease and Surgery Institute) 33 $48,279.94
Cleveland Clinic: RidersForCure 1 $300.00
Cleveland Clinic: Skins Team (DPSI) 1 $1,880.00
Cleveland Clinic: South Russell 2 $1,787.00
Cleveland Clinic: TA Riders (Recruiting) 4 $2,375.00
Cleveland Clinic: Taussig Cyclotrons 162 $249,157.89
Cleveland Clinic: Team Cancer Building - Buildings and Properties 53 $100,002.53
Cleveland Clinic: Team Cleveland Clinic 42 $210,173.00
Cleveland Clinic: Team GUKI (Urology and Kidney Institute) 3 $3,406.88
Cleveland Clinic: Team Marymount 2 $3,107.00
Cleveland Clinic: Team South Pointe 6 $2,640.00
Cleveland Clinic: The A Team 2 $1,125.00
Cleveland Clinic: Thoracic Fantastic 4 $3,155.00
Cleveland Clinic: Women’s Health Institute 2 $1,380.00
Cleveland Indians 48 $126,629.43
Cleveland Research 8 $13,345.70
Cleveland StARTup Collective 31 $239,274.18
Cliffs Natural Resources 6 $40,960.00
Clot R CHOP 2 $2,092.00
Dave Kovach 2 $1,785.00
Deloitte 14 $14,069.00
Ed and Sandy 2 $1,625.00
Fathom 44 $23,494.00
fire food and drink 6 $6,734.00
FIT Technologies 3 $2,890.00
Fitz Flyers 3 $4,820.00
Flying Frank 3 $14,960.00
Frantz Ward 1 $1,678.00
Func 2 $5,400.00
GARDINER 4 $9,230.00
Genentech Peddlers 8 $14,712.00
Glenmede 5 $5,615.00
Go Hoss or Go Home 2 $2,860.00
HD 1 $50.00
Hileman Group 10 $12,360.85
Hudson Velo 53 $61,245.00
Jones Day 29 $72,107.25
K & D 2 $2,450.00
KINETiQ DIGITAL 18 $52,025.00
KPMG 35 $48,820.00
Lerner Foundation 25 $62,473.00
Lilly Oncology 6 $3,165.00
LisandTim4aCure 3 $1,540.00
Living Proof 3 $5,495.00
Merrill Lynch/Bank of America 12 $13,326.00
MMG (Merrymeeting Inc) 3 $5,325.00
MOEN 8 $41,990.00
More Than Gourmet 2 $2,265.00
Murray Pranksters 2 $2,543.00
Nestle 13 $9,245.00
Platform-Road Warriors 2 $1,256.00
POWERSTEP Peddlers 6 $7,165.00
Proud*Respect*Serve*Protect 2 $3,320.00
Sail On 1 $2,736.00
Sandy’s Domestiques 23 $53,012.17
Sherwin-Williams 8 $16,172.50
Smucker’s 4 $6,836.00
Special K 1 $560.00
Spin For Stu 23 $68,547.58
Squire Patton Boggs 33 $45,597.59
Start to Finish Fitness 2 $4,600.00
SyncShow 2 $4,976.00
Team 1:9 11 $15,940.00
Team Brawner 3 $4,331.00
Team Bruell 3 $3,175.01
Team Calfee 9 $20,890.00
Team EY 15 $8,155.00
Team Hiccup 2 $7,940.00
Team JACK 2 $60.00
Team Karlovec Hirobel 4 $5,980.00
Team Key 60 $81,783.00
TEAM LEXUS Metro | Akron/Canton 11 $13,031.00
Team MD Insider 4 $4,755.00
Team Oatey 27 $37,330.50
Team Oswald 15 $23,518.57
Team PAC 11 $19,154.41
Team Progressive 2 $4,737.42
Team Proton Spin - QED 18 $24,237.50
Team PwC 39 $53,288.15
Team RSM 34 $45,083.68
Team Shotgun! WGAR! 1 $1,150.00
Team Spin / Litzler Automation 5 $10,590.55
Team Tommy O!!! 6 $6,447.30
Team TrishyStrong 25 $25,370.00
Team Ulmer & Berne LLP 5 $8,403.00
Team Wendy 8 $13,815.00
Team WKYC 8 $8,048.33
Team MCPc 3 $3,500.00
Terry’s Troops 6 $6,414.30
The Riverside Company 33 $198,724.15
Thompson Hine 5 $7,860.00
Tim in Training 1 $1,070.00
Two Spoke Girls 2 $2,250.00
Velo Vino 11 $17,113.00
VeloFemme-Litzler 6 $31,536.00
Vocon 16 $41,587.00
Wheeling for Healing 9 $28,230.57
Yankovitz Family 5 $2,810.00
 

2017 Top Fundraising Riders

  1. Stewart Kohl
    $163,223
  2. Paul Dolan
    $71,614
  3. Joanne Cohen
    $61,167
  4. Bob Rich
    $37,990
  5. Terry Sullivan
    $34,372
  6. Len Pagon
    $32,522
  7. Mike Maroone
    $26,900
  8. Sally Wajahn
    $25,530
  9. Bill Mulligan
    $24,610
  10. Craig Manchen
    $23,940

2017 Top Fundraising Virtual Riders

  1. Jaroslaw Maciejewski
    $17,050
  2. Alan Lichtin
    $7,520
  3. Ken Guest
    $6,910
  4. Jame Abraham
    $6,445
  5. Lynn Hubach
    $4,483
  6. Zumi Pig
    $4,105
  7. Chelsea Irvin
    $4,013
  8. Jorge Garcia
    $3,895
  9. Nicole Peters
    $3,771
  10. Charis Eng
    $3,637

2017 Teams                                                                       

Team Name Riders & Virtual Riders Total Dollars Raised
Acumen Solutions 1 $1,065.00
ADCOM CYCLING TEAM 32 $37,238.00
American Greetings 7 $9,185.00
BDO USA 15 $42,205.00
Beans & Weenies 4 $7,345.00
BIG GALOOTS BICYCLE CLUB (Rich Foods) 74 $159,908.00
Brandmuscle 32 $24,817.00
Cardinal Health 29 $45,339.00
Case Comprehensive Cancer Center 110 $99,252.00
CBIZ 19 $24,550.00
CBRE Cleveland 26 $63,793.00
Cedar Creek Grille 1 $1,925.00
Charles' Cycling Club 5 $4,470.00
CLE Connect 4 $2,998.00
Cleveland Clinic: "A Team" (Akron General) 2 $4,495.00
Cleveland Clinic Children’s 23 $20,915.00
Cleveland Clinic Florida - Maroone Cancer Center 10 $33,220.00
Cleveland Clinic International 15 $13,005.00
Cleveland Clinic: Akron General 19 $31,753.00
Cleveland Clinic: Bike Like a Champion Today (Chief of Staff Division) 5 $4,695.00
Cleveland Clinic: BOC Independence (Finance) 5 $9,812.00
Cleveland Clinic: Brainiacs (Neurological Institute) 13 $7,980.00
Cleveland Clinic: CCF InfoTech 3 $10,455.00
Cleveland Clinic: Education Institute 2 $2,479.00
Cleveland Clinic: Fairview Hospital 11 $10,735.00
Cleveland Clinic: H60 (Neuroscience) 3 $2,340.00
Cleveland Clinic: Lerner Research Institute 41 $35,311.00
Cleveland Clinic: Make it Rain (Philanthropy Institute) 75 $104,590.00
Cleveland Clinic: Nursing Institute 11 $17,326.00
Cleveland Clinic: ONEHR Rides (Human Resources) 8 $13,988.00
Cleveland Clinic: Pepsin Pedalers (Digestive Disease & Surgery Institute) 30 $27,971.00
Cleveland Clinic: Prolin' For A Cure (Center for Clinical Genomics) 12 $8,985.00
Cleveland Clinic: Region Legion (Regional Hospitals) 17 $21,106.00
Cleveland Clinic: TA Riders (Talent Acquisition) 11 $7,008.00
Cleveland Clinic: Taussig Cyclotrons (Taussig Cancer Center) 202 $327,258.00
Cleveland Clinic: Team Cleveland Clinic 16 $138,336.00
Cleveland Clinic: Team South Pointe 7 $3,615.00
Cleveland Clinic: Ventures (Innovations) 7 $7,867.00
Cleveland Clinic: Wheels of Steel (Buildings and Properties) 39 $73,630.00
Cleveland Indians 84 $190,938.00
Cleveland Research 5 $5,490.00
Cleveland StARTup Collective 14 $99,817.00
Cliffs Natural Resources 6 $6,605.00
Colliers International 2 $6,855.00
Dad and Daughter 2 $825.00
Donley Turner HEC 23 $29,159.00
Ed and Sandy 2 $1,500.00
Faster Than a Speeding Turtle 2 $1,050.00
Fathom 31 $19,488.00
Fidelity Roadfrogs 3 $2,600.00
FIT Technologies 4 $4,505.00
Fitz Flyers 2 $2,400.00
Flying Frank 4 $8,536.00
Frantz Ward 1 $1,000.00
Func 2 $3,905.00
GARDINER 6 $22,350.00
Genentech Peddlers 8 $9,591.00
Glenmede 6 $9,515.00
Harness Cycle 18 $7,965.00
Hudson Velo 27 $41,779.00
Integra Connect 8 $9,285.00
Jones Day 35 $89,581.00
Kick Some Carcinoid 2 $2,000.00
KPMG 33 $55,534.00
Lilly Oncology 4 $3,232.00
Living Proof 3 $4,155.00
McDonald Hopkins 10 $8,935
MegaCycle 2 $500.00
Merrill Lynch/Bank of America 12 $26,620.00
MOEN 17 $23,374.00
MOTOWN coMOTION 3 $1,440.00
Murray Pranksters 2 $2,022.00
Nestle 6 $9,527.00
No Training 1 $185.00
Oatey 30 $32,466.00
Perpetual Peddlers 1 $50.00
Proud*Respect*Serve*Protect 3 $3,130.00
RamseyStrong-25m 3 $2,610.00
RamseyStrong-Virtual 1 $25.00
Robots & Pencils 27 $50,325.00
Sail On 1 $2,498.00
Sandy’s Domestiques 33 $72,654.00
Shaker Neighbors 5 $3,200.00
Sherwin-Williams 14 $23,966.00
Siladi 2 $2,315.00
Smucker’s 4 $5,983.00
Spin For Stu 40 $102,126.00
Spins for Nanja 3 $1,935.00
Spudded Sprockets 3 $3,120.00
Squire Patton Boggs 20 $19,370.00
Start to Finish Fitness 2 $4,045.00
Sweet Serenade 2 $1,645.00
Team 1:9 11 $13,555.00
Team Ancora 8 $17,586.00
Team Berson-Sokol 4 $8,184.00
Team Brawner 3 $4,025.00
Team Calfee 9 $20,614.00
Team Deloitte 18 $12,305.00
Team EverGreen 21 $13,670.00
Team EY 12 $8,914.00
Team Grant Thornton 7 $7,735.00
Team Hiccup 1 $1,000.00
Team Hileman 16 $16,534.00
Team InterContinental 11 $9,718.00
Team Key 74 $81,568.00
TEAM LEXUS Metro | Akron/Canton 18 $20,964.00
Team Litzler 11 $42,936.00
Team Mueller 4 $2,475.00
Team OHIO 3 $840.00
Team Oswald 17 $27,659.00
TEAM PAC pedaling against cancer 10 $12,069.00
Team Partners Karlovec 2 $3,600.00
Team Progressive3 3 $4,071.00
Team Proton Spin - QED 11 $24,745.00
Team PwC 39 $56,591.00
Team RSM 31 $36,842.00
Team Shotgun 1 $2,230.00
Team TEC 4 $2,665.00
Team Ten30 3 $1,527.00
Team TrishyStrong 35 $24,085.00
Team Ulmer & Berne LLP 15 $15,179.00
Team Wendy 8 $12,380.00
Team WKYC 14 $18,240.00
Terry’s Troops 5 $8,975.00
The A/C Team 5 $1,780.00
The Lerner Foundation 27 $70,774.00
The Riverside Company 64 $294,987.00
Tim and Tyler in Training 2 $1,039.00
Velo Vino 19 $18,684.00
Vicious Cycles 2 $751.00
Vocon 26 $55,517.00
Wheeling for Healing 8 $31,310.00
Yes We CAN!!!...kick cancer!! 8 $5,839.00
 

Living Hope

Our Living Hope community of Riders, Virtual Riders and Volunteers who are current cancer patients, people in recovery and those who are cancer survivors bring to VeloSano stories of their journeys and their own personal reasons for “Why I Ride”.

Living Hope

This special community provides Hope for recovery; Hope for a cure; and Hope for the day when there will be no cancer. Every year we unite to share in their journeys and to celebrate recovery, remission and support those who are battling cancer. Every year we Bike to cure.

We honor our Living Hope community — you inspire us!

Living Hope

Our Partners

The financial and/or in-kind support of our partners allows VeloSano to successfully and safely operate the event, as well as allocate every dollar raised by participants directly to cancer research at Cleveland Clinic. Thank you to each and every one of our amazing partners — we couldn’t do this without you!

Founding Partners

Cleveland Indians
Donna Stewart Kohl

Supporting Partners

JACK Entertainment
MCPc Family Charities
UN1TUS
Adcom Group
Jones Day Foundation
Lexus
Zack Bruell Events

Contributing

Adcom Group
Advance OHIO
Zack Bruell Events
cleveland.com
DiGeronimo Companies
JACK Entertainment
KeyBank
Michelob ULTRA
Panera Bread
UN1TUS

Spoke

Brandmuscle
Lilly Oncology
American Greetings
ASSOS
Cardinal Health
Hileman Group
Hilton Cleveland
Master Lock
RSM
Smucker's
The Lerner Foundation
Van Cleef & Arpels

Pedal

Lilly Oncology
Barbasol - Pure Silk
Donley's
Epic
GOJO
MD Insider
Sodexo
Staples
The Stielau Foundation
Turner
Genentech

Axle

FIJI Water
Genentech
Amgen
Brandmuscle
CBRE
Coca-Cola
Fidelity
Giant Eagle
Gross Residential
MCPc Family Charities
QED
Rich's
EY
Forest City
Squire Patton Boggs

Media

Bicycling
Cleveland's Star 102
ESPN Cleveland
Fox SportsTime Ohio
Lamar
Pandora
Spectrum
iHeart Media WGAR
WKYC

Special Thanks

Bike Cleveland
City of Cleveland Ohio
Cleveland Clinic Emergency Services Institue
Cleveland Clinic Sports Health
Cleveland Metroparks
City of Cleveland Water
Destination Cleveland
Donald Martens & Sons Ambulance Service, Inc.
Independence Excavating
Petitti Garden Centers
South East Golf Car Company

Big Wheelers

Big Wheelers
 

 

Our VeloSano Big Wheelers are Riders who at least double their minimum fundraising commitment or Virtual Riders who raise $1,000 or more. We have more and more Big Wheelers every year and are truly grateful to them for going above and beyond as they fundraise for cancer research at Cleveland Clinic. The below lists will allow you to view the 335 Big Wheelers for VeloSano 3 (2016) as well as the 407 Big Wheelers for VeloSano 4 (2017). Each year we treat our Big Wheelers with some special garb, so if you see them sporting their gear around town be sure to give them a big thank you – they’re a big deal!

 
A
Cathy Abbott
Abel Abraham
Adith Abraham
Jame Abraham
Pete Accorti
Vlad Agranovich
Jay Akkul
Geoff Aldridge
Benito Alvarez
Kevin Aman
Michelle Amato
David Anderson
John Anderson
Marc Apple
Keith Arian
Greg Avis
B
Toni Bacon
Mark Baker
Laura Baranek
Wael Barsoum
Mike Bauer
Craig Belec
Robert Bender
Heidi Benson
Ryan Berg
Chris Bergman
Judy Bird
James Bitar
Brian Bolwell
Mike Bosner
Erin Brady Curtis
Gary Brahler
Katy Brahler
Beth Brandon
Mark Brandt
Mark Brown
Francesca Brunello Nomina
G. Thomas Budd
Anthony Buehrer
Patti Butler
Marc Byrnes
C
Julie Callsen
Denise Carkhuff
Hetty Carraway
Kara Carter
Robert Case
Samuel Chao
Armando Chardiet
Mike Chase
Veronica Chua
Gino Ciarimboli
Tom Cicarella
Brad Clemons
Michael Coburn
Nan Cohen
Joanne Cohen
Chandler Converse
Tom Corrick
Paul Cseplo
Mike Cucciarre
William Currin
Paul Cusato
D
Curtis Danburg
Tyler Danburg
Jon Dandes
Jerry Davidson
Jillian Davis
Heather Dawson
Conor Delaney
James Deuschle
Paul Dolan
Debbie Donley
Kevin Dooley
Dave Doren
Peter Dougherty
John Dougherty
Marianne Douglas
Kenneth Douglas
Coleen Dowdall
Don Dreier
Tara Dzialak
E
Tricia Easton
Jack Efta
Jeff Ehrbar
Caroline El Sanadi
Jamie Elberson
James Ellis
Charis Eng
Doug England
Bassam Estfan
Eric Evers
F
David Faturos
Nicole Fetko
Lauren Fight
Kathryn Fong
Judy Ann Forbes
Emily Forgach
Matthew Friske
Hiroyuki Fujita
John Fung
Beth Fung
Brendan Fung
Bryan Furlong
G
Nicholas Gambone
Pamela Gamier
Jorge Garcia
Stan Gerson
Samir Ghousheh
Melissa Giambrone
Mathew Gleeson
Robert Goehrke
Chris Gorman
Dave Grinnell
Petros Grivas
Ken Guest
Lindsay Guzowski
H
Stephen Hallam
Susan Halloran
Lauren Hanna
Jeffrey Harcourt
Briana Harper
Marc Harrison
Kathy Hart
Georgia Hatzis
Dan Haynes
Graham Hearns
Christina Hein
Matthew Hein
Helen Heine
Matt Heisey
Nicole Hilbert
Michael Hollabaugh
Janice Horn
Lynn Hubach
Casey Huselton
I
Adam Ihlenfield
Chelsea Irvin
 
J
Jeremy Jacobs
Michael Jacobs
Jordan Jakab
Count Maillot Jaune
Terry Jenkins
Steve Jones
Kathryn Jones
Andy Jones
Nikhil Joshi
K
Matt Kalaycio
Steve Karklin
Paul Katz
Matt Keppler
Alok Khorana
Ethan Khorana
John Kingston
Colleen Kipfstuhl
Joshua Klarfeld
Frank Klein
Ryan Knaack
Greg Kobilarcsik
Stewart Kohl
Donna Kohl
Steven Kohn
Lindsey Kolesky
Alex Kolosiwsky
Jeremy Komasz
Zachary Komoroski
Shlomo Koyfman
Lisa Krejci
Amy Kubacki
Jeff Kula
L
April LaRow
Justin Lathia
Andrew Latimer
Kathryn Lavelle
Susan LeGrand
Bill Leonard
Alan Lichtin
Matt Litzler
Hien Liu
Francis Loth
Anna Lowenstein
Daniel Luciano
Barbara Ludlow
Kevin Lynn
M
Jaroslaw Maciejewski
Paul Madonia
Amanda Maggiotto
Andrea Maher
Navneet Majhail
Alane Malerick
Craig Manchen
Keith Mannor
Joel Marcus
Mike Maroone
Craig Martin
Keith McCrae
Megan McElroy
Jennifer McGreevy
Linda McHugh
Kevin McIntyre
Jamie McKeon
Matt McKeon
Stacey McKinley
Dan McNeil
Bishoy Mikhail
Tom Milewski
Laura Mimura
Jessica Mocilnikar
Edward Moore
Lori Moore
Mike Mountain
Ed Muckley
Greg Mueller
Paula Muhic
Bill Mulligan
Bill Munday
Erin Murphy
Rob Myers
N
Jen Neundorfer
Dave Neundorfer
 
O
Mary Pat O’Connor
Larry Oliveri
Scott Olson

P
Len Pagon
Armida Parala-Metz
Chris Peer
Abbey Perl
Nicole Peters
Michael Petras
Michael A Petras
James Picariello
Zumi Pig
Brad Pohlman
Larry Pollock
Julia Pollock
R
Ben Rababy
Jason Radel
Craig Reagor
Chris Rebant
Kristin Ricci
Bob Rich
Barney Rich
Paul Rich
Howard Rich
Bill Riter
Tom Roe
Mark Rood
Mark Ross
Sharon Roth
Tom Roulston
Joshua Rowe
S
John Saada
Donna Sakony
Kristin Samsa
Karen Sands
Yogen
Saunthararajah
Joe Scaminace
Mike Schaefer
Morgan Schreiber
Brittany Schreiber
Kandis Schreiber
Ryan Schreiber
Sarah Schwarz
Abram Schwarz
Matt Segal
David Seiger
Chirag Shah
Marybeth Shamrock
Marc Shapiro
Nima Sharifi
Scott Shaw
Dale Shepard
Renee Singley
Mark Snyder
Amanda Snyder Jacobs
James Soukup
Timothy Spiro
Dean Spong
Nick Stambula
Stacey Starnes
Kevin Stephans
James Stevenson
Rich Stovsky
Joe Stratton
Todd Stroud
Jagadeesh
Sudarshana
John Suh
John Sukis
Terry Sullivan
Bart Swain
Sheila Swartzlander
T
Robert Tablack
Michele Taylor
Rahul Tendulkar
Judy Thaxton-Borlin
Eric Tischler
Kelly Tompkins
Luke Torre-Healy
Michael Travis
Colleen Tredway
Mary Tredway
Chris Troianos
Thomas Turco
Frank Turek
Shane Turner
Rodney Twells
U
Barry Underwood

V
Jason Valent
Steve Viny
W
Robert Waitkus
Sally Wajahn
Margo Walker
Jim Wamelink
Julianne Wanda
Jerry Warsaw
Jeffrey Wasserman
Arlene Watson
Ron Weinberg
Dana Weiss
Jim Whalen
Morris Wheeler
Stephen Willoughby
Kristie Winfield
Nelson Wittenmyer
Blair Wood
Mary Wright
Cheryl Wright
Y
Christine Young
Brian Young
James Young

Z
Marta Zamiska
Rio Zamiska
Dan Zelman
 
 
A
Tom Abelson
Jame Abraham
Anouk Ackerman
David Adelstein
Ross Agnor
Geoff Aldridge
Alex Almasan
Michelle Amato
David Anderson
John Anderson
Dana Angelini
D Alexander Antolino
Keith Arian
Leslye Arian
Anne Avis
Greg Avis
Sandy Avis
B
Megan Backhus
Mark Baker
Andrew Barkley
John Bartels
Jennifer Bates
Pat Behm
Craig Belec
Mark Bellamy
Pamela Bellamy
David Benson
Linsey Berberich
Chris Bergman
Jeff Berlin
Brandon Berlingieri
Will Biggar
Judy Bird
Dan Bluhm
Brian Bolwell
Terry Bork
Mike Bosner
Nancy Bradshaw
Erin Brady Curtis
Beth Brand
Mark Brown
Francesca Brunello Nomina
Wynette Bryant
G. Thomas Budd
Aeron Burns
Marc Byrnes
Micki Byrnes
C
Joycelin Canavan
Madison Capito
Allison Carney
Hetty Carraway
Gina Casalinova
Robert Case
Samuel Chao
Michael Charlillo
Mike Chase
Philip Cherian
Joseph Chura
Loren Chylla
Tom Cicarella
Heidi Coburn
Michael Coburn
Joanne Cohen
Nan Cohen
Lance Colie
Tom Collins
Bill Colvin
Charley Connolly
Chandler Converse
Megan Croke
Paul Cseplo
Mike Cucciarre
Jeffrey Culliton
William A. Currin
Paul Cusato
Kevin Custer
D
Jonathan Dandes
Rob Dean
Phyllis Desantis
James Deuschle
Rocco Dilillo
Ruthann Dilillo
Giorgio DiPaolo
Katy Dix Brahler
Paul Dolan
Jane Donahue
Debbie Donley
Kevin Dooley
Dave Doren
Peter Dougherty
Coleen Dowdall
Don Dreier
Tara Dzialak
E
Chris Easton
Tricia Easton
Jeff Ehrbar
Caroline El Sanadi
Jamie Elberson
Charis Eng
Doug England
Emily English
Bassam Estfan
F
David Faturos
Peter Faulhaber
Tom Feher
Julie Fetto
Lauren Fight
Ryan Fisher
Judy Ann Forbes
Rebecca Frazier
Tom Freeman
Evin Friedlander
Jennifer Friedler
Hiroyuki Fujita
Beth Furlong
Bryan Furlong
Diana Fusco
G
Pamela Gamier
Jorge Garcia
Phil Gard
David Garson
Geoff Gates
Kierston Gedeon
Matthew Geiger
Aaron Gerds
Stan Gerson
Charlie Giambrone
Melissa Giambrone
Bill Gisel
Ben Giust
Mathew Gleeson
Chris Gorman
Dave Grinnell
Jerry Grisko
Petros Grivas
Ken Guest
David Gunning
Lindsay Guzowski
H
Logan Haberny
Nick Hajdin
Susan Halloran
Aaron Hamilton
Betty Hamilton
Jeniver Hamilton
Miles Hamilton
Kelly Hancock
Lauren Hanna
Laurie Haramis
Kathy Hart
Erika Hawley
Brendan Hearns
Graham Hearns
Kelsey Hearns
Kerianne Hearns
Kathy Heflin
Matt Heisey
Mark Henderson
Frank Hendl
David Henkel
Kathryn Hickner
Liz Holden
Annica Howard
Jacque Hoyt
Lynn Hubach
Brian Hurtuk
Casey Huselton
Bryan Hyla
I
Lauren Imperial
Chelsea Irvin
Bud Isaacson
Sandy Isleib
 
J
Jeremy Jacobs
Michael Jacobs
Lesley Johnson
Tad Johnson
Steve Jones
Sherry Jones
K
Matt Kalaycio
Steve Karklin
Paul Katz
Laura Keglovic
Kennedy Kerr
Joe Kessler
Alok Khorana
Ethan Khorana
John Kingston
Tracy Kipfstuhl
Joshua Klarfeld
Frank Klein
David Kleinman
Ryan Knaack
Greg Kobilarcsik
Omer Koc
Kelsey Koch
Donna Kohl
Stewart Kohl
Steven Kohn
Alan Kolesky
Lindsey Kolesky
Jeremy Komasz
Mary Kornelakis
Shlomo Koyfman
Lisa Krejci
Matt Kroh
Amy Kubacki
Casey Kula
Jeff Kula
Lisa Kula
L
Leslie Lang
Kylie Lavalley
Tom LeBuhn
Jacqueline Lee
Joe Lee
Dennis Lehman
Brian Leonard
Bill Leonard
Alan Lichtin
Matt Litzler
Mike Livermore
Eric Logan
Anna Lowenstein
Daniel Luciano
Kim Lupkin
John Lynch
Kevin Lynn
M
Jaroslaw Maciejewski
John MacIntosh
MaryBeth Madonia
Paul Madonia
Amanda Maggiotto
Matt Maguire
Navneet Majhail
Fekru Makonnen
Alane Malerick
Kate Malone
Lindsay Malone
Craig Manchen
Keith Mannor
Steve Manos
Matt Manosky
Bindu Manyam
Joel Marcus
Mike Maroone
Craig Martin
Sydney Martin
Anthony Mastroianni
Tom Mayor
Keith McCrae
John McCullough
Linda McHugh
Kevin McIntyre
Jamie Mckeon
Stacey McKinley
TJ McManamon
Michael McMicken
Dan McNeil
Omar Mian
Bishoy Mikhail
Tom Milewski
Laura Mimura
Robbie Mocilnikar
Manoj Monga
Emily Monteleone
Ed Moore
Ed Muckley
Greg Mueller
Bill Mulligan
MaryBeth Musser
Raymond Muzic
Rob Myers
Jake Myron
N
Bradley Nelson
Ivan Nemecek
Dave Neundorfer
Jen Neundorfer
Vicky Newman
 
O
William Oatey
Beverly O'Neill

P
Richard Padgett
Len Pagon
William Palliser
Armida Parala-Metz
Susan Parker
Rob Pawlak
Holly Pederson
Chris Peer
Jane Peer
Eric Pelander
Melisa Peline
Bob Pelley
Nathan Pennell
Louis B. Perry
Tracy Pesho
Matt Peters
Nicole Peters
Jeff Petrowski
Zumi Pig
Julia Pollock
Larry Pollock
Kristen Powaski
Jennifer Prugh
R
Jason Radel
Michael Ranalli
Craig Reagor
Sharon Reichart
Kristin Ricci
Bob Rich
Paul Rich
Vicki Rich
Robert Rich III
Jennifer Rieker
Ron Ring
Bill Riter
Lynda Roberts
Tom Roe
Robin Rood
Mark Ross
Allen Roth
Tom Roulston
Maria Rybak
S
Eliza Saada
John Saada
Donna Sakony
Christy Samaras
Kevin Samuels
Karen Sands
Don Saxon
Yogen Saunthararajah
Mike Schaefer
Peter Scheid
Brittany Schreiber
Kandis Schreiber
Morgan Schreiber
Ryan Schreiber
Abram Schwarz
Sarah Schwarz
Freddy Scott
Holly Scott
Jacob Scott
Matt Segal
Sandy Selby
Dale Shepard
Mike Simoniello
Renee Singley
Douglas Smith
Kent Snyder
Amanda Snyder Jacobs
Timothy Spiro
Dana Stachowski
Nick Stambula
Cliff Stein
James Stevenson
Rich Stovsky
Hannah Strominger
Marianne Stroud
Todd Stroud
Jagadeesh Sudarshana
John Suh
John Sukis
Terry Sullivan
Bart Swain
Ray Swanson
Sheila Swartzlander
T
Robert Tablack
Melissa Talty
Judy Thaxton-Borlin
Jenna Thomas
Raquel Timm
Owen Timura
Eric Tischler
Paul Tolchinsky
Michael Travis
Colleen Tredway
Chris Troianos
Kate Tullio
Frank Turek
Rodney Twells
V
Kathleen Vagi
Lori Vajdich
Jason Valent
Vinay Varadan
Rose Viny
Steve Viny
W
Robert Waitkus
Sally Wajahn
Margo Walker
Jim Wamelink
Jerry Warsaw
Laura Wehrmann
Dana Weiss
Andy Wheat
Morris Wheeler
Michael White
Bryce Williams
Melissa Wilson
Kristie Winfield
Tyler Winfield
Matthew Winters
Nelson Wittenmyer
Mary Wong
Genevieve Frances Woodland
Mary Wright
Donald Wroble
X
Ping Xia
 

Z
Marta Zamiska
Rio Zamiska
Daniel Zaucha
 

The Team



 

2016 Co-Chairs

Stewart Kohl The Riverside Company
Paul Dolan Cleveland Indians
John Saada Jones Day

2016 Medical Chair

Brian J. Bolwell, M.D.

2016 Honorary Co-Chairs

John Anderson WKYC Channel 3
Norma Lerner The Lerner Foundation

Team VeloSano (pictured above left to right)

Beth Brand, Director
Nicole Peters, Senior Director
Mohammed Farunia, Associate Director
Kandis Schreiber, Director

2016 Steering Committee

Pete Accorti Talan Products
Phil Alexander Brandmuscle
Greg Avis Summit Partners
Mike Bauer Master Lock Company LLC
Bill Berardino Metro Lexus | Lexus of Akron-Canton
Mark Brandt RSM US LLP
Aeron Burns Lilly Oncology
Marc Byrnes Oswald Companies
Kara Carter JumpStart, Inc.
Loren Chylla Adcom
Michael Coburn Nestle USA
Joanne Cohen Cleveland Clinic
Chandler Converse CBRE
Delos Cosgrove, M.D. Cleveland Clinic
Sam Covelli Covelli Enterprises
Dave Doren Cleveland Clinic
Peter Dougherty Merrill Lynch
Don Dreier Donley’s
Caroline El Sanadi Case Western Reserve University
Trina Evans KeyBank / KeyCorp
Hiroyuki Fujita QED
Samir Ghousheh Cardinal Health
Dave Gilbert Greater Cleveland Sports Commission & Positively Cleveland
Jerry Grisko CBIZ, Inc.
Jack Haas Sensical Companies/UN1TUS
Brian Hall Innogistics
Pat Hallinan Moen
Marc Harrison, M.D. Cleveland Clinic
Tom Hileman Hileman Group
Andy Jones MCPc
Steve Jones Cleveland Clinic
Denise Kramer Zack Bruell Events
Matt Litzler C.A. Litzler Co.
Craig Manchen
Valarie McCall City of Cleveland
Linda McHugh Cleveland Clinic
Bill Mulligan Primus Capital
Jen Neundorfer flashstarts
Len Pagon Next Sparc LLC
Larry Pollock Lucky Stars Partners LLC
Tim Richards Cleveland’s New 102 WDOK-FM
Renee Singley The Lerner Foundation
John Sinnenberg Cyprium Capital
LT Slater Takoda Group LLC
Jacob VanSickle Bike Cleveland
Steve Viny Envision Waste Services LLC
Morris Wheeler Drummond Road Capital


 

Founder

Stewart Kohl The Riverside Company

2017 CO ChairS

Paul Dolan Cleveland Indians
John Saada Jones Day

2017 Medical Chair

Brian J. Bolwell, M.D.

2017 Honorary Co-Chairs

John Anderson WKYC Channel 3
Norma Lerner The Lerner Foundation

Team VeloSano (pictured above left to right)

Beth Brand, Director
Nicole Peters, Senior Director
Mohammed Farunia, Associate Director
Kandis Schreiber, Director

2017 Steering Committee

Phil Alexander Brandmuscle
John Anderson WKYC Channel 3
Greg Avis Summit Partners
Toni Bacon U.S. Department of Justice
Mark Brandt RSM US LLP
Aeron Burns Lilly Oncology
Kara Carter JumpStart, Inc.
Loren Chylla Adcom
Michael Coburn Nestle USA
Joanne Cohen Cleveland Clinic
Chandler Converse CBRE
Debbie Donley Vocon
Dave Doren Cleveland Clinic
Peter Dougherty Merrill Lynch
Don Dreier Donley’s
Caroline El Sanadi Diamsome Pharmaceuticals
Hiroyuki Fujita Quality Electrodynamics (QED)
Bryan Furlong KPMG
Samir Ghousheh FSASTORE.COM
Tom Hileman Hileman Group
Andy Jones MCPc
Steve Jones Cleveland Clinic
Joshua Klarfeld Ulmer & Berne LLP
Denise Kramer Zack Bruell Events
Jim LaRose House of LaRose
Bill Leonard Oswald Companies
Matt Litzler C.A. Litzler Co.
Scot Lowry Fathom
Craig Manchen
Valarie McCall City of Cleveland
Francois McGillicuddy Fox Sports Ohio
Linda McHugh Cleveland Clinic
Bill Mulligan Primus Capital
Jen Neundorfer flashstarts
Len Pagon Robots + Pencils
Larry Pollock Lucky Stars Partners LLC
Mark Ross PwC
Renee Singley Chenoweth The Lerner Foundation
Mitch Thompson Squire Patton Boggs
Rodney Twells Compass Group of Wells Fargo Advisors
Jacob VanSickle Bike Cleveland
Steve Viny Envision Waste Services LLC
Jerry Warsaw SureSite
Morris Wheeler Drummond Road Capital
Keith Williams ESPN Cleveland

Thank you for being part of the VeloSano family.

Your support helps advance innovative cancer research at Cleveland Clinic, making a positive impact on the lives of patients and their families. Thank you! And don’t forget to save the date for VeloSano 5, taking place July 20 – 22, 2018! Sign up to be notified when registration is open.